VISEN Pharmaceuticals (2561.HK) Stock Competitors & Peer Comparison
See (2561.HK) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2561.HK | HK$19.20 | -2.09% | 2.1B | -14.85 | -HK$1.29 | N/A |
| 1276.HK | HK$55.05 | -5.00% | 365.4B | 75.43 | HK$0.73 | +0.41% |
| 3692.HK | HK$31.80 | -4.10% | 192.8B | 31.03 | HK$1.02 | +1.36% |
| 2196.HK | HK$16.22 | -4.02% | 60.8B | 7.81 | HK$2.08 | +2.77% |
| 0874.HK | HK$15.83 | -0.44% | 39.3B | 7.86 | HK$2.01 | +6.04% |
| 0867.HK | HK$12.17 | -3.41% | 29.6B | 17.85 | HK$0.68 | +2.68% |
| 1513.HK | HK$26.22 | -2.74% | 28.7B | 10.03 | HK$2.61 | +6.27% |
| 3933.HK | HK$9.16 | -4.28% | 18B | 7.26 | HK$1.26 | +3.26% |
| 0013.HK | HK$17.45 | -5.93% | 15B | 4.21 | HK$4.14 | N/A |
| 2637.HK | HK$187.00 | -3.01% | 14.7B | 63.39 | HK$2.95 | N/A |
Stock Comparison
2561.HK vs 1276.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1276.HK has a market cap of 365.4B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1276.HK trades at HK$55.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1276.HK's P/E ratio is 75.43. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1276.HK's ROE of +0.13%. Regarding short-term risk, 2561.HK is less volatile compared to 1276.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 1276.HK's competition here
2561.HK vs 3692.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 3692.HK has a market cap of 192.8B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 3692.HK trades at HK$31.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 3692.HK's P/E ratio is 31.03. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 3692.HK's ROE of +0.17%. Regarding short-term risk, 2561.HK is less volatile compared to 3692.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 3692.HK's competition here
2561.HK vs 2196.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2196.HK has a market cap of 60.8B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2196.HK trades at HK$16.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2196.HK's P/E ratio is 7.81. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2196.HK's ROE of +0.09%. Regarding short-term risk, 2561.HK is less volatile compared to 2196.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 2196.HK's competition here
2561.HK vs 0874.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0874.HK has a market cap of 39.3B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0874.HK trades at HK$15.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0874.HK's P/E ratio is 7.86. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0874.HK's ROE of +0.08%. Regarding short-term risk, 2561.HK is more volatile compared to 0874.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 0874.HK's competition here
2561.HK vs 0867.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0867.HK has a market cap of 29.6B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0867.HK trades at HK$12.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0867.HK's P/E ratio is 17.85. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0867.HK's ROE of +0.09%. Regarding short-term risk, 2561.HK is less volatile compared to 0867.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0867.HK's competition here
2561.HK vs 1513.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1513.HK has a market cap of 28.7B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1513.HK trades at HK$26.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1513.HK's P/E ratio is 10.03. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1513.HK's ROE of +0.14%. Regarding short-term risk, 2561.HK is less volatile compared to 1513.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 1513.HK's competition here
2561.HK vs 3933.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 3933.HK has a market cap of 18B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 3933.HK trades at HK$9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 3933.HK's P/E ratio is 7.26. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 3933.HK's ROE of +0.13%. Regarding short-term risk, 2561.HK is less volatile compared to 3933.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 3933.HK's competition here
2561.HK vs 0013.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0013.HK has a market cap of 15B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0013.HK trades at HK$17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0013.HK's P/E ratio is 4.21. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0013.HK's ROE of +0.37%. Regarding short-term risk, 2561.HK is less volatile compared to 0013.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0013.HK's competition here
2561.HK vs 2637.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2637.HK has a market cap of 14.7B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2637.HK trades at HK$187.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2637.HK's P/E ratio is 63.39. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2637.HK's ROE of N/A. Regarding short-term risk, 2561.HK is less volatile compared to 2637.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 2637.HK's competition here
2561.HK vs 9989.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 9989.HK has a market cap of 14.2B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 9989.HK trades at HK$4.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 9989.HK's P/E ratio is 21.28. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 9989.HK's ROE of +0.03%. Regarding short-term risk, 2561.HK is less volatile compared to 9989.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 9989.HK's competition here
2561.HK vs 1558.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1558.HK has a market cap of 14B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1558.HK trades at HK$15.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1558.HK's P/E ratio is 26.47. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1558.HK's ROE of +0.06%. Regarding short-term risk, 2561.HK is more volatile compared to 1558.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 1558.HK's competition here
2561.HK vs 1681.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1681.HK has a market cap of 11.4B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1681.HK trades at HK$13.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1681.HK's P/E ratio is 10.67. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1681.HK's ROE of +0.24%. Regarding short-term risk, 2561.HK is less volatile compared to 1681.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 1681.HK's competition here
2561.HK vs 0719.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0719.HK has a market cap of 9.1B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0719.HK trades at HK$6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0719.HK's P/E ratio is 14.68. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0719.HK's ROE of +0.05%. Regarding short-term risk, 2561.HK is less volatile compared to 0719.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0719.HK's competition here
2561.HK vs 6887.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 6887.HK has a market cap of 9B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 6887.HK trades at HK$28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 6887.HK's P/E ratio is 43.75. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 6887.HK's ROE of N/A. Regarding short-term risk, 2561.HK is less volatile compared to 6887.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 6887.HK's competition here
2561.HK vs 0460.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0460.HK has a market cap of 7.8B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0460.HK trades at HK$0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0460.HK's P/E ratio is 39.70. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0460.HK's ROE of +0.04%. Regarding short-term risk, 2561.HK is less volatile compared to 0460.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0460.HK's competition here
2561.HK vs 0570.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0570.HK has a market cap of 7.6B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0570.HK trades at HK$1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0570.HK's P/E ratio is -26.50. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0570.HK's ROE of -0.02%. Regarding short-term risk, 2561.HK is less volatile compared to 0570.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0570.HK's competition here
2561.HK vs 2575.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2575.HK has a market cap of 6.5B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2575.HK trades at HK$12.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2575.HK's P/E ratio is -20.66. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2575.HK's ROE of -0.21%. Regarding short-term risk, 2561.HK is less volatile compared to 2575.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 2575.HK's competition here
2561.HK vs 2877.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2877.HK has a market cap of 6.2B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2877.HK trades at HK$8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2877.HK's P/E ratio is 5.99. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2877.HK's ROE of +0.12%. Regarding short-term risk, 2561.HK is more volatile compared to 2877.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 2877.HK's competition here
2561.HK vs 2652.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2652.HK has a market cap of 4B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2652.HK trades at HK$15.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2652.HK's P/E ratio is 1548.00. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2652.HK's ROE of N/A. Regarding short-term risk, 2561.HK is less volatile compared to 2652.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 2652.HK's competition here
2561.HK vs 2552.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2552.HK has a market cap of 2.6B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2552.HK trades at HK$2.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2552.HK's P/E ratio is 2.40. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2552.HK's ROE of +1.07%. Regarding short-term risk, 2561.HK is less volatile compared to 2552.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 2552.HK's competition here
2561.HK vs 6896.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 6896.HK has a market cap of 2.4B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 6896.HK trades at HK$3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 6896.HK's P/E ratio is 6.91. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 6896.HK's ROE of +0.19%. Regarding short-term risk, 2561.HK is more volatile compared to 6896.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 6896.HK's competition here
2561.HK vs 2633.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2633.HK has a market cap of 2.1B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2633.HK trades at HK$1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2633.HK's P/E ratio is 6.90. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2633.HK's ROE of +0.13%. Regarding short-term risk, 2561.HK is more volatile compared to 2633.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 2633.HK's competition here
2561.HK vs 1061.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1061.HK has a market cap of 1.6B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1061.HK trades at HK$2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1061.HK's P/E ratio is 5.22. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1061.HK's ROE of +0.14%. Regarding short-term risk, 2561.HK is less volatile compared to 1061.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 1061.HK's competition here
2561.HK vs 2161.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2161.HK has a market cap of 1.6B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2161.HK trades at HK$1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2161.HK's P/E ratio is 8.61. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2161.HK's ROE of +0.19%. Regarding short-term risk, 2561.HK is more volatile compared to 2161.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 2161.HK's competition here
2561.HK vs 2348.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 2348.HK has a market cap of 1.5B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 2348.HK trades at HK$1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 2348.HK's P/E ratio is 2.48. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 2348.HK's ROE of +0.06%. Regarding short-term risk, 2561.HK is more volatile compared to 2348.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 2348.HK's competition here
2561.HK vs 8049.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 8049.HK has a market cap of 1.3B. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 8049.HK trades at HK$2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 8049.HK's P/E ratio is 6.62. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 8049.HK's ROE of +0.12%. Regarding short-term risk, 2561.HK is more volatile compared to 8049.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 8049.HK's competition here
2561.HK vs 1349.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1349.HK has a market cap of 805.8M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1349.HK trades at HK$2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1349.HK's P/E ratio is -11.79. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1349.HK's ROE of -0.07%. Regarding short-term risk, 2561.HK is less volatile compared to 1349.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 1349.HK's competition here
2561.HK vs 1652.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1652.HK has a market cap of 761.5M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1652.HK trades at HK$1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1652.HK's P/E ratio is -4.08. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1652.HK's ROE of -0.03%. Regarding short-term risk, 2561.HK is more volatile compared to 1652.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 1652.HK's competition here
2561.HK vs 0503.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0503.HK has a market cap of 750.6M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0503.HK trades at HK$1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0503.HK's P/E ratio is 13.77. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0503.HK's ROE of +0.07%. Regarding short-term risk, 2561.HK is less volatile compared to 0503.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0503.HK's competition here
2561.HK vs 0239.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0239.HK has a market cap of 723M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0239.HK trades at HK$2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0239.HK's P/E ratio is 7.80. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0239.HK's ROE of +0.13%. Regarding short-term risk, 2561.HK is more volatile compared to 0239.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 0239.HK's competition here
2561.HK vs 3737.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 3737.HK has a market cap of 556.9M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 3737.HK trades at HK$0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 3737.HK's P/E ratio is 5.47. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 3737.HK's ROE of +0.02%. Regarding short-term risk, 2561.HK is less volatile compared to 3737.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 3737.HK's competition here
2561.HK vs 0897.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0897.HK has a market cap of 345.5M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0897.HK trades at HK$0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0897.HK's P/E ratio is 63.27. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0897.HK's ROE of +0.00%. Regarding short-term risk, 2561.HK is more volatile compared to 0897.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 0897.HK's competition here
2561.HK vs 1011.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1011.HK has a market cap of 256M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1011.HK trades at HK$0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1011.HK's P/E ratio is -1.80. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1011.HK's ROE of +0.09%. Regarding short-term risk, 2561.HK is more volatile compared to 1011.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 1011.HK's competition here
2561.HK vs 8329.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 8329.HK has a market cap of 194.6M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 8329.HK trades at HK$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 8329.HK's P/E ratio is 11.85. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 8329.HK's ROE of -0.06%. Regarding short-term risk, 2561.HK is more volatile compared to 8329.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 8329.HK's competition here
2561.HK vs 0455.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0455.HK has a market cap of 193.5M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0455.HK trades at HK$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0455.HK's P/E ratio is -3.15. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0455.HK's ROE of -0.08%. Regarding short-term risk, 2561.HK is more volatile compared to 0455.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 0455.HK's competition here
2561.HK vs 0858.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0858.HK has a market cap of 188.8M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0858.HK trades at HK$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0858.HK's P/E ratio is 1.24. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0858.HK's ROE of -1.55%. Regarding short-term risk, 2561.HK is more volatile compared to 0858.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 0858.HK's competition here
2561.HK vs 1498.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 1498.HK has a market cap of 121.4M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 1498.HK trades at HK$0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 1498.HK's P/E ratio is -3.99. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 1498.HK's ROE of -0.30%. Regarding short-term risk, 2561.HK is more volatile compared to 1498.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 1498.HK's competition here
2561.HK vs 0911.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 0911.HK has a market cap of 113.5M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 0911.HK trades at HK$0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 0911.HK's P/E ratio is 86.56. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 0911.HK's ROE of +0.01%. Regarding short-term risk, 2561.HK is less volatile compared to 0911.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 2561.HK.Check 0911.HK's competition here
2561.HK vs 8622.HK Comparison July 2026
2561.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2561.HK stands at 2.1B. In comparison, 8622.HK has a market cap of 89.2M. Regarding current trading prices, 2561.HK is priced at HK$19.20, while 8622.HK trades at HK$0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2561.HK currently has a P/E ratio of -14.85, whereas 8622.HK's P/E ratio is -18.62. In terms of profitability, 2561.HK's ROE is -0.31%, compared to 8622.HK's ROE of -0.10%. Regarding short-term risk, 2561.HK is more volatile compared to 8622.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2561.HK.Check 8622.HK's competition here